NextCure, Inc. (NXTC)

NASDAQ: NXTC · IEX Real-Time Price · USD
4.72
+0.01 (0.21%)
Jun 29, 2022 11:02 AM EDT - Market open
0.21%
Market Cap 130.97M
Revenue (ttm) n/a
Net Income (ttm) -73.46M
Shares Out 27.75M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,398
Open 4.70
Previous Close 4.71
Day's Range 4.61 - 4.79
52-Week Range 3.25 - 9.18
Beta 0.15
Analysts Buy
Price Target 13.35 (+182.8%)
Earnings Date Aug 4, 2022

About NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1;... [Read more...]

Industry Biotechnology
IPO Date May 9, 2019
Employees 87
Stock Exchange NASDAQ
Ticker Symbol NXTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for NXTC stock is "Buy." The 12-month stock price forecast is 13.35, which is an increase of 182.84% from the latest price.

Price Target
$13.35
(182.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinica...

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on...

BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure Provides Business Update and Reports First Quarter 2022 Financial Results

BELTSVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...

NextCure to Present at the BofA Securities 2022 Healthcare Conference

BELTSVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

NextCure to Present at 21st Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

BELTSVILLE, Md., March 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure to Present at The JMP Securities Hematology and Oncology Summit

BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunot...

BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update

BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual ...

BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure Announces Three New Members of its Scientific Advisory Board

BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure Announces Publication of Preclinical Data for NC410

BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure Announces New Appointments to its Board of Directors

BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-labe...

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat can...

NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies

NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tu...